A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Clinical trial NCT06546670 · RECRUITING

Trial details

NCT number: NCT06546670
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease

Start date: 2024-08-15
Primary completion: 2028-05-01
Enrollment: 161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.